CanFite Biopharma (CANF)
(Real Time Quote from BATS)
$4.18 USD
+0.55 (15.15%)
Updated Jun 14, 2024 10:36 AM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Brokerage Reports
Can-Fite Biopharma Ltd [CANF]
Reports for Purchase
Showing records 201 - 217 ( 217 total )
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Diagnostic Development Underway to Unlock CF101 Potential; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
2013 Results; 2014 Data Should Drive U.S. Visibility; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
CF102 Prepped for Phase II; Flurry of CF101 Activity in Background
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Not Only Does CF101 Work, but it Works Better in Treatment Naive Patients
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Dry-Eye Misses; Focus on the RA Win; Buy on Weakness
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Major Shot Across the Biologics'' Bow; RA Phase II Nails It; Target to $28
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
US Patent Granted for A3AR Biomarker; Expect Critical Data By Month End
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Major Answers This Month for CF101; Should be a Nice Ride; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J